<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               <BR>                  WARNING: <BR>                  QT PROLONGATION AND SUDDEN DEATHS <BR>               <BR>               <BR>                  <BR>                     <BR>                        Tasigna prolongs the QT interval. Prior to Tasigna administration and periodically, monitor for hypokalemia or hypomagnesemia and correct deficiencies (5.2). Obtain ECGs to monitor the QTc at baseline, seven days after initiation, and periodically thereafter, and follow any dose adjustments (5.2, 5.3, 5.6, 5.13).<BR>                        <BR><BR>                     <BR>                     <BR>                        Sudden deaths have been reported in patients receiving nilotinib (5.3). Do not administer Tasigna to patients with hypokalemia, hypomagnesemia, or long QT syndrome (4, 5.2). <BR>                        <BR><BR>                     <BR>                     <BR>                        Avoid use of concomitant drugs known to prolong the QT interval and strong CYP3A4 inhibitors (5.7). <BR>                        <BR><BR>                     <BR>                     <BR>                        Patients should avoid food 2 hours before and 1 hour after taking dose (5.8).<BR>                     <BR>                  <BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                        <BR>                           WARNING: <BR>                           QT PROLONGATION AND SUDDEN DEATHS<BR>                        <BR>                        <BR>                           See full prescribing information for complete boxed warning.<BR>                        <BR>                        <BR>                           <BR>                              Tasigna prolongs the QT interval.  Prior to Tasigna administration and periodically, monitor for hypokalemia or hypomagnesemia and correct deficiencies (5.2). Obtain ECGs to monitor the QTc at baseline, seven days after initiation, and periodically thereafter, and follow any dose adjustments (5.2, 5.3, 5.6, 5.13).<BR>                              <BR><BR>                           <BR>                           <BR>                              Sudden deaths have been reported in patients receiving nilotinib (5.3).  Do not administer Tasigna to patients with hypokalemia, hypomagnesemia, or long QT syndrome (4, 5.2).  <BR>                              <BR><BR>                           <BR>                           <BR>                              Avoid use of concomitant drugs known to prolong the QT interval and strong CYP3A4 inhibitors (5.7). <BR>                              <BR><BR>                           <BR>                           <BR>                              Patients should avoid food 2 hours before and 1 hour after taking dose (5.8).<BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>